In prostate cancer, the combination of delphinidin and tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) has been found to activate caspase pathways, relying on the activation of death receptor 5 (DR5) and cleavage of HDAC3. Here, TNFSF10 is linked to prostate carcinoma.